Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions - SPIRIT II: Results Through 3 Years


The goal of the SPIRIT II study was to evaluate the safety and efficacy of the XIENCE V everolimus-eluting cobalt chromium coronary stent compared with the TAXUS paclitaxel-eluting stent among patients with de novo coronary lesions.